LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials

BACKGROUND: SARS-CoV-2 (COVID-19) has disrupted healthcare service delivery globally. CAB+RPV LA is a novel, long-acting antiretroviral therapy (ART) currently in development and is administered intramuscularly monthly or every 2 months by a healthcare provider. COVID-19 and the resultant restrictio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: D'Amico, Ronald, Benn, Paul, McCoig, Cynthia C, Griffith, Sandy, Hudson, Krischan J, Sutton, Kenneth, Harrington, Conn M, Wu, Sterling, Williams, Will, Hove, Kai S, Martin Espanol, Carlos, Fricker, E Jane, Patel, Parul, Margolis, David
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Late Breaker Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777408/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa515.1905
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars